A new analysis estimates that losing as little as 5% weight can lead to substantial savings in health care costs elsewhere.

GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as an alternative to the traditional — and often ineffective — advice to “eat less and exercise more.

The demand for GLP-1 drugs (like Wegovy and several others) continues to grow. Despite this escalating demand, the prices for some of these popular drugs are actually dropping, according to a new report from the U.